alexa Should Deubiquitinating Enzymes be Targeted for Therapy? | OMICS International | Abstract
ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Editorial

Should Deubiquitinating Enzymes be Targeted for Therapy?

Sokol V Todi1* and Chittaranjan Das2
1Department of Pharmacology and Department of Neurology, Wayne State University School of Medicine, USA
2Department of Chemistry, Purdue University, USA
Corresponding Author : Sokol V Todi
Assistant Professor, Department of Pharmacology and Department of Neurology
Wayne State University School of Medicine
540 E. Canfield, Scott Hall Rm 6105, Detroit
Michigan 48201, USA
Tel: +1(313)577-1173
E-mail: [email protected]
Received August 16, 2012; Accepted August 17, 2012; Published August 23, 2012
Citation: Todi SV, Das C (2012) Should Deubiquitinating Enzymes be Targeted for Therapy? Clinic Pharmacol Biopharm. 1:e108. doi:10.4172/2167-065X.1000e108
Copyright: © 2012 Todi SV, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Effective, non-toxic therapies for many diseases, including malignancies, metabolic syndromes and age-dependent neurodegeneration remain elusive, though not for lack of effort from scientists all over the world.

Recommended Conferences
Share This Page
Top